Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial

Premenopausal women receiving chemotherapy or endocrine treatment for early breast cancer are at increased risk for cancer treatment induced bone loss (CTIBL). The aim of the randomized, double-blind ProBONE II trial was to investigate whether a 2-year adjuvant treatment with 4  mg intravenous zoledronic acid (ZOL) every 3 months versus placebo would prevent CTIBL after a five-year period.

https://www.thebonejournal.com/article/S8756-3282(18)30239-4/fulltext?rss=yes

Source: Bone - June 13, 2018 Category: Orthopaedics Authors: Ioannis Kyvernitakis, Peter Herbert Kann, Friederike Thomasius, Olaf Hars, Peyman Hadji Tags: Full Length Article Source Type: research